Last mentioned: Mar 9, 2026
$85M Private Placement
Company announces oversubscribed funding to accelerate clinical trials.
Platform Validation
Preclinical data for lead AATD program shows high editing efficiency.
Merger Completion
Korro Bio becomes a public entity via merger with Freeline Therapeutics.
Korro Bio has announced an oversubscribed $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. This capital injection is expected to extend the company's cash runway and accelerate the clinical development of its lead programs targeting genetic diseases.
Korro Bio has announced an oversubscribed $85 million private placement to accelerate its proprietary RNA editing platform and clinical development. The funding provides a significant runway for the company's lead program, KRRO-110, targeting Alpha-1 Antitrypsin Deficiency.